Rocket Lab ($RKLB) is now tracked here, and the thing worth putting on the page first is not the record quarter. It is the trade the company agreed on 29 June: $8.0 billion of enterprise value for Iridium Communications, paid in cash and in its own stock.
Iridium's revenue over the twelve months to 30 June was $884.2 million. Rocket Lab's own, over the same twelve months, was $769.1 million. Rocket Lab is acquiring a business that books 115% of its revenue — and paying for it partly in a currency the market values on a completely different scale.
At $72.95, the 20 August close, Rocket Lab's enterprise value is about $44.3 billion — market capitalisation of $46.6 billion on the 639.1 million diluted shares the company's own per-share figures use, less roughly $2.4 billion of net cash. That is 57.6 times trailing revenue. Iridium at $8.0 billion is 9.0 times trailing revenue. The buyer's own multiple is 6.4 times the one it is paying.
What is established
- The agreement, dated 28 June 2026, gives Iridium holders $27.00 in cash plus Rocket Lab stock at an exchange ratio set by a collar, for a notional $54.00 per Iridium share.
- The exchange ratio is defined precisely: 0.4000 shares if the reference price is at or below $67.50; $27.00 divided by the price between $67.50 and $112.50; 0.2400 shares at or above $112.50.
- The reference price is not today's price. It is the ten-trading-day volume-weighted average ending two full trading days before closing, and closing is expected in mid-2027.
- Enterprise value of approximately $8.0 billion, the parties' own figure. Iridium carries a term loan with $1.775 billion outstanding at 30 June that both sides are seeking to leave in place.
- A $3.6 billion 364-day bridge from Deutsche Bank and Wells Fargo backs the cash leg, and on 13 August Rocket Lab opened an equity distribution agreement for up to $1,944,369,826 of stock to begin replacing it.
- Antitrust cleared on 12 August; the Form S-4 and the FCC licence-transfer applications were filed the same week.
- Rocket Lab's June quarter: revenue $234.1 million, up 62% year on year, gross margin 36.1%, backlog $2.36 billion, and third-quarter revenue guided to $250–265 million.
The collar is the small number
The collar is what the market has been watching, because at $72.95 the stock sits only 7.5% above its $67.50 floor. Below that floor the ratio stops floating, Iridium holders take fewer dollars of value, and the notional $54.00 stops being $54.00.
Run the share count across the whole band and the alarm mostly goes away:
- At the $112.50 cap: 0.2400 × 105.96 million Iridium shares = 25.4 million Rocket Lab shares, 4.0% of the current diluted count.
- At $72.95: 0.3701 × 105.96 million = 39.2 million shares, 6.1%.
- At the $67.50 floor: 0.4000 × 105.96 million = 42.4 million shares, 6.6%.
That is the entire range. A 40% move in Rocket Lab's reference price, from the cap to the floor, changes the stock consideration by 2.6 percentage points of the share count. The collar is doing its job — it is a cap on dilution, and the cap is tight.
The number that actually moves is the one nobody put a band around. The $1.94 billion equity distribution agreement opened on 13 August is, at $72.95, about 26.7 million shares — 4.2% of the count on its own, and it is only the first instalment of replacing a $3.6 billion bridge. Stock consideration plus that programme is 10.3% of the diluted count before a dollar of permanent debt is priced. The collar bounds the part of the deal that was negotiated; the financing of the cash leg was not bounded by anything.
The denominator on the cash leg
The cash half is 105,960,383 Iridium shares × $27.00 = $2.861 billion.
Rocket Lab held $2.39 billion of cash, cash equivalents and marketable securities at 30 June — a balance sheet transformed in the first half, up from $1.10 billion at the end of 2025. The cash consideration alone is 1.2 times every liquid dollar the company holds. That is the whole reason a $3.6 billion bridge exists, and the whole reason the equity programme opened five days after the quarter.
So the deal is not "Rocket Lab pays with a rich stock." It is "Rocket Lab pays 53% in cash it does not have, and the rich stock is what refinances the borrowing."
Why the multiple gap is the argument, not a criticism
A 57.6x buyer acquiring a 9.0x target is normally read as arbitrage: issue expensive paper, buy cheap earnings, watch the blended multiple do the work. It is worth being precise about what is and is not established here.
What is established is the arithmetic above. What is not established is that the two multiples are measuring the same thing. Rocket Lab's 57.6x prices a launch and space-systems business growing 62% year on year with a backlog up 137%; Iridium's 9.0x prices a mature subscriber network with 2.55 million users and a term loan. Nobody outside the two companies knows what Rocket Lab intends to do with Iridium's L-band spectrum, and that option — not the subscriber revenue — is what Beck has described as the reason for the deal. We are not going to put a number on the spectrum. It has no disclosed valuation, no comparable transaction inside this agreement, and any figure quoted for it today is invented.
What the gap does establish is the scale of the shift. Combined trailing revenue would be about $1.65 billion, more than double Rocket Lab standalone, with roughly 54% of it coming from a business bought at a seventh of the acquirer's multiple. Whatever the blended multiple settles at, the company being valued at $44 billion of enterprise value after mid-2027 is a materially different one from the company being valued at that today.
Against the tracked comparisons
Two other direct-to-device names are tracked here and both frame the same market differently. AST SpaceMobile ($ASTS) is building a constellation from nothing and burned $694.8 million in the June quarter to do it; SpaceX ($SPCX) funds its own from a launch business that already earns. Rocket Lab is choosing the third route — buying an operating network and its spectrum rather than building either — and the price of that shortcut is $8.0 billion of enterprise value and a financing stack it has not yet assembled.
There is no published R40 model for Rocket Lab, so nothing here is reconciled against one and no fair value is implied by any figure in this piece.
What to watch
- The ten-day VWAP window in mid-2027, not the price today. The collar reads on it, and everything before it is noise for the exchange ratio.
- How much of the $1.94 billion equity programme is actually drawn, and at what prices. Shares issued there are unbounded by any collar and are the larger dilution.
- What replaces the $3.6 billion bridge. Permanent debt keeps the share count down and puts interest against a company that has never run leveraged; more equity does the reverse.
- Whether Iridium's term loan stays in place. Both sides said they would seek amendments to keep the $1.775 billion facility outstanding — that is $1.775 billion Rocket Lab does not have to refinance.
- Third-quarter revenue against the $250–265 million guide, and whether GAAP gross margin holds the 29–31% the company guided after printing 36.1% in June.
Sources and provenance. The exchange-ratio definition, the $67.50 and $112.50 collar bands, the 0.4000 and 0.2400 caps, the $27.00 cash consideration and the ten-trading-day VWAP reference-price mechanic are quoted from the merger agreement dated 28 June 2026 filed with the SEC. The $54.00 notional per share, the approximately $8.0 billion enterprise value, the $3.6 billion bridge commitment and the 2.55 million Iridium subscribers are from the parties' joint announcement of 29 June 2026. The $1,944,369,826 equity distribution agreement, the Hart-Scott-Rodino expiry on 12 August, the Form S-4 filing and the FCC applications are disclosed in Rocket Lab's filings of 13 August 2026, and Iridium's $1.775 billion term loan balance at 30 June is disclosed there. Rocket Lab's June-quarter revenue, gross margin, backlog, balance-sheet cash and securities, debt, share counts and third-quarter guidance are from its second-quarter 2026 results published 10 August 2026. Iridium's 105,960,383 shares outstanding is the cover-page figure from its quarterly report filed 22 July 2026, and its revenue figures are from its own filed results. Trailing-twelve-month revenue of $884.2 million for Iridium and $769.1 million for Rocket Lab, the enterprise values of $44.3 billion and the 57.6x and 9.0x multiples, the 6.4x ratio between them, the 115% and 54% revenue shares, the $2.861 billion cash leg, the 1.2x liquidity cover, the 25.4 / 39.2 / 42.4 million share counts and their 4.0% / 6.1% / 6.6% dilution, the 26.7 million ATM shares and the 10.3% combined figure are R40 arithmetic on those disclosed numbers. Share price of $72.95 is the close of 20 August 2026; market capitalisation uses the 639.1 million share count the company's own per-share figures are struck on, which includes its Series A convertible participating preferred. No R40 model exists for this company, so no figure here is modelled, and no value is assigned to Iridium's spectrum because none is disclosed.
